FibroGen Inc (FGEN) Insider K Peony Yu Sells 2,851 Shares

FibroGen Inc (NASDAQ:FGEN) insider K Peony Yu sold 2,851 shares of the firm’s stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $43.70, for a total transaction of $124,588.70. Following the completion of the transaction, the insider now owns 162,086 shares in the company, valued at $7,083,158.20. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

K Peony Yu also recently made the following trade(s):

  • On Monday, November 6th, K Peony Yu sold 7,500 shares of FibroGen stock. The shares were sold at an average price of $55.37, for a total transaction of $415,275.00.
  • On Wednesday, October 4th, K Peony Yu sold 15,000 shares of FibroGen stock. The shares were sold at an average price of $60.00, for a total transaction of $900,000.00.
  • On Monday, October 2nd, K Peony Yu sold 40,000 shares of FibroGen stock. The shares were sold at an average price of $54.63, for a total transaction of $2,185,200.00.

FibroGen Inc (FGEN) traded up $0.45 during midday trading on Friday, reaching $42.40. 2,858,243 shares of the company’s stock traded hands, compared to its average volume of 581,447. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.16. FibroGen Inc has a 52 week low of $19.25 and a 52 week high of $60.15.

Several analysts have issued reports on the stock. BidaskClub lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. ValuEngine lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Stifel Nicolaus restated a “buy” rating and issued a $80.00 price target on shares of FibroGen in a research report on Thursday, September 14th. Mizuho assumed coverage on shares of FibroGen in a research report on Wednesday, October 4th. They issued a “neutral” rating and a $61.00 price target on the stock. Finally, Jefferies Group restated a “buy” rating and issued a $75.00 price target on shares of FibroGen in a research report on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. FibroGen presently has an average rating of “Buy” and a consensus target price of $65.67.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quantbot Technologies LP bought a new position in shares of FibroGen during the 2nd quarter worth about $128,000. Oppenheimer Asset Management Inc. lifted its holdings in shares of FibroGen by 112.6% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock worth $237,000 after acquiring an additional 2,336 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in shares of FibroGen by 15.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after acquiring an additional 696 shares during the period. BBR Partners LLC bought a new position in shares of FibroGen during the 3rd quarter worth about $299,000. Finally, Teacher Retirement System of Texas bought a new position in shares of FibroGen during the 3rd quarter worth about $299,000. Institutional investors own 57.43% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3099081/fibrogen-inc-fgen-insider-k-peony-yu-sells-2851-shares.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.